INTRODUCTION
============

In many cells types, such as epithelial cells, fibroblasts, and smooth muscle cells, stimulation by growth factors promotes the formation of a unique type of structure called the circular dorsal ruffle (CDR; [@B10]). CDRs (also called waves or ring ruffles) are F-actin-- and cortactin-rich membrane protrusions that form transiently at the dorsal surface of the cell in response to growth factor stimulation ([@B50]). CDRs form very rapidly and only once after growth factor treatment ([@B44]), and one of their most notable features is their circularity ([@B50]). CDRs appear at the dorsal surface, where they expand and then constrict toward their center in a coordinated manner to maintain a circular appearance, until they finally close, typically 5--30 min after stimulation ([@B44]). They are different from the widely characterized ruffles forming at the cell edge, sometimes referred to as peripheral ruffles (PRs). PRs are usually linear structures that persist and undergo cycles of assembly and disassembly ([@B10]). They also extend dorsally but are located at the periphery of the cell, typically at the leading edge ([@B1]). Despite their differences, CDRs share many structural components with PRs, including actin, dynamin2, cortactin, N-WASP, and Arp2/3, among others ([@B44]).

The function of CDRs has not been conclusively established. Previous work has shown that CDRs may be involved in cell migration, when cells switch from a static to a migratory phenotype ([@B44]; [@B61]). Other reports associate the formation of CDRs with macropinocytosis and internalization of membrane receptors such as receptor tyrosine kinases (RTKs) and integrins ([@B20]; [@B19]; [@B53]; [@B29]).

The signaling events downstream of the platelet-derived growth factor (PDGF) receptor that drive CDR formation require the function of phosphoinositide 3-kinase (PI3K; [@B74]; [@B34]) and the small GTPase Rac ([@B34]; [@B27]; [@B69]). Rac1-/- cells are unable to form CDRs, suggesting that Rac1 is essential for their formation ([@B69]). However, overexpression of constitutively active Rac1 induced PRs but no CDRs ([@B45]), suggesting other signaling pathways working in parallel with Rac1 are required for CDR formation.

Although many of the components of the CDRs have been identified, the molecular mechanisms controlling their formation and disappearance have not been fully characterized. We hypothesized that RhoG, a Rac1-related small GTPase, was involved in CDR formation because RhoG has been associated with the formation of actin-rich ruffles at the dorsal surface of the cell ([@B26]; [@B39]; [@B21]; [@B65]; [@B75]). These RhoG-mediated dorsal ruffles typically form as intersecting, reticulated linear ruffles and are phenotypically different than CDRs ([@B6]; [@B21]). However, they share many molecular components with CDRs. In addition, RhoG activity has been shown to associate with processes such as macropinocytosis, phagocytosis, bacterial internalization, and leukocyte transmigration, all of which share similarities with CDR formation ([@B71]; [@B17]; [@B21]; [@B54]; [@B65]). RhoG has also been shown to play roles during cell migration, neurite outgrowth, cell survival, and changes in gene expression, suggesting that its cellular functions are complex ([@B39], [@B37]; [@B22]; [@B48]; [@B52]; [@B70]; [@B75]; [@B49]).

Here we describe the role of RhoG and its guanine nucleotide exchange factor (GEF), Trio, in the regulation of CDR formation. We show that, in vascular smooth muscle cells, RhoG and Trio control the size of CDRs in a Rac1-independent manner and that perturbing their expression levels and/or activity also affects micropinocytosis, receptor internalization, and cell migration.

RESULTS
=======

RhoG expression modulates the formation of CDRs
-----------------------------------------------

In smooth muscle cells, PDGF treatment induces the formation of CDRs ([@B27]; [@B35]). Because RhoG was previously associated with peripheral dorsal ruffles and other actin-rich dorsal structures, we hypothesized that RhoG may play a role during CDR formation. To test our hypothesis, we examined CDR formation in rat aortic smooth muscle cells (A7r5) transfected with either control or RhoG-specific small interfering RNA (siRNA; RhoG knockdown \[KD\]). Initially, we looked at the morphology of the CDRs in a time course after PDGF treatment. Our results show that in both control and RhoG KD cells, CDRs form with similar kinetics, appearing as early as 1 min, peaking at ∼2.5 min, and starting to decrease at 5 min ([Figure 1, A and C](#F1){ref-type="fig"}, and Supplemental Movies S1 and S2). By 15 min, most CDRs had disappeared, and no CDRs were detected at later time points. Even though RhoG knockdown was very efficient ([Figure 1B](#F1){ref-type="fig"}), silencing RhoG expression did not inhibit the rate of CDR formation, as we had hypothesized. However, at both 2.5 and 5 min after PDGF addition, the percentage of cells displaying CDRs was significantly lower in the absence of RhoG ([Figure 1C](#F1){ref-type="fig"}).

![PDGF-induced CDR formation is affected by RhoG silencing. (A) A7r5 cells were transfected with siRNA against RhoG (RhoG KD) or with a nontargeting siRNA (CTRL). After 72 h, cells were serum starved for 2 h and stimulated with PDGF-BB (20 ng/ml) for 1, 2.5, and 5 min. Cells were fixed and processed for immunofluorescence using cortactin (red) as marker of dorsal ruffles, Alexa 488--phalloidin (green) to stain F-actin, and Hoechst (blue) to visualize nuclei. Representative images of the 2.5-min time point. Scale bar, 20 μm. (B) KD efficiency was tested for each experiment by immunoblot in cell lysates 72 h after transfection. (C) Number of cells with CDRs expressed as percentage of cells that stained positive for at least one CDR. (D) Average number of CDRs per cell (in cells positive for CDRs). (E) Average CDR area. Black bars, CTRL cells; gray bars, RhoG KD. Results are shown as mean ± SEM from three independent experiments (≥100 cells per condition/experiment).](1768fig1){#F1}

Typically, most PDGF-treated cells form between one and five CDRs, with an average of approximately two per cell. In RhoG KD cells, the average number of CDRs per cell was not significantly different than in CTRL cells ([Figure 1D](#F1){ref-type="fig"}). The most striking effect of silencing RhoG expression related to the area of the CDRs ([Figure 1, A and E](#F1){ref-type="fig"}). In the absence of RhoG, the average area of the CDRs decreased almost twofold. At 2.5 min after PDGF treatment, the average CDR area was 951.22 ± 90.49 μm^2^ in CTRL cells compared with 502.27 ± 30.50 μm^2^ in RhoG KD cells ([Figure 1E](#F1){ref-type="fig"}). This decrease is observed at every time point tested, ruling out the possibility that the CDRs form early or are in the process of disassembling at the time of the measurement ([Figure 1E](#F1){ref-type="fig"}). To determine whether these results were specific for smooth muscle cells, we silenced RhoG in a human fibroblast cell line, MRC5, and tested their ability to form CDRs in response to PDGF (Supplemental Figure S1). Our results show that silencing RhoG (Supplemental Figure S1A) has a similar effect in fibroblasts as in smooth muscle cells, with significantly fewer cells forming CDRs (Supplemental Figure S1C), which were smaller in area (Supplemental Figure S1, B and D). Overall our results suggest that RhoG plays a role in both the formation of CDRs and the regulation of their size.

Dynamics of CDR formation in live cells
---------------------------------------

Time-lapse microscopy analysis corroborated the results from fixed cells, with the maximum area of CTRL CDRs being significantly larger than that of CDRs in Rho KD cells ([Figure 2, A and B](#F2){ref-type="fig"}). Quantitative analysis shows that, in most cases, CDRs appear at or close to their maximum size and start closing right away ([Figure 2A](#F2){ref-type="fig"} and Supplemental Movies S1 and S2). Occasionally, a small increase in area is observed before closing starts, but with our live-imaging setup, we rarely observe CDR expansion. Our results show that in RhoG KD cells, the lifetime of the CDRs is significantly shorter ([Figure 2C](#F2){ref-type="fig"}), which means that they close significantly faster than CTRL CDRs, although with similar kinetics ([Figure 2D](#F2){ref-type="fig"}). These results suggest that the speed at which they close may be comparable in terms of area/time. Using the area for each ruffle at each time point, we calculated the rate of closing in CTRL and RhoG KD cells and found that the closing rates are almost identical in both conditions, suggesting that the faster closing is the result of a smaller starting area, which closes at the same rate ([Figure 2E](#F2){ref-type="fig"}). This size reduction was consistent throughout the lifetime of the CDRs, ruling out the possibility that the time course of CDR formation is affected in RhoG KD cells (e.g., CDRs formed earlier/later or disassembled faster). Taken together, these results suggest that RhoG controls the maximum CDR size without affecting their closing speed.

![Dynamics of CDR formation in live cells. A7r5 cells transfected with siRNA targeting RhoG (RhoG KD) or with a nontargeting siRNA (CTRL) were analyzed by time-lapse microscopy immediately after the addition of 20 ng/ml PDFG-BB. Pictures were taken at intervals of 35 s, and CDR properties were evaluated using ImageJ. (A) A representative series for CTRL and RhoG KD after formation and disassembly of CDRs. Scale bar, 20 μm. (B) Average maximal area that each CDR reached during the total time recorded. (C) Average CDR lifetime. (D) Maximum area of each CDR was standardized to 1, and CDR disassembly was then plotted vs. time. Complete disassembly is achieved significantly faster in average CTRL cells than with RhoG KD (\**p* \< 0.0001) but with similar kinetics. Results for A--C are expressed as mean ± SEM from two independent experiments (a combined total of 72 cells were analyzed in CTRL, and 82 cells were analyzed in RhoG KD). (E) For each CDR, the disassembly rate was calculated from the slope of a linear regression calculated for each CDR disassembly event. The difference between these two sets of data is not significant.](1768fig2){#F2}

PDGF induces RhoG activation
----------------------------

The activation of the small GTPases RhoA, Rac1, and Cdc42 in response to PDGF was described by [@B24] (RhoA), [@B11] and [@B57] (Rac1), and [@B36] (Cdc42). In contrast, the activation of RhoG in response to PDGF has not been tested. However, RhoG has been shown to respond to other growth factors such as epidermal growth factor ([@B58]). Our results show that RhoG is rapidly activated after PDGF stimulation in A7r5 cells. Activation is detected as early as 1 min and returns to basal level after 5 min ([Figure 3, A and B](#F3){ref-type="fig"}). We obtained similar results in human fibroblasts (MRC5; Supplemental Figure S1E). Of interest, CDR formation and RhoG activity follow a similar pattern in response to PDGF ([Figures 1C](#F1){ref-type="fig"} and [3, A and B](#F3){ref-type="fig"}), with RhoG activity peaking slightly earlier than the CDRs. This suggests that RhoG activity may be implicated during CDR formation. To corroborate that RhoG activation depends on the kinase activity of PDGF receptor (PDGFR), we pretreated the cells with the PDGFR inhibitor AG1295. Our results show that AG1295 impairs PDGF-mediated RhoG activation, suggesting that it depends on PDGFR kinase activity ([Figure 3, C and D](#F3){ref-type="fig"}).

![PDGF induces RhoG activation. (A) A7r5 cells were serum starved for 2 h and then stimulated with PDGF-BB (20 ng/ml) for 1, 2.5, and 5 min. Active RhoG (RhoG-GTP) was then precipitated from total lysates using GST-ELMO and immunoblotted with RhoG antibodies. (B) Quantification of three independent assays. (C) Cells pretreated with 10 μM AG1295 to inhibit PDGFR before PDGF-BB stimulation. (D) Quantification of three independent assays. Serum-starved cells were pretreated with 10 μM PP2 (E), 25 μM LY294002 (G), or 10 μM U0126 (I) for 30 min and then stimulated with PDGF for 1 min. Active RhoG (RhoG-GTP) was then measured as in A. Phospho--Tyr-416 Src, phospho--Ser-473 Akt, and phospho--Thr-202/Tyr-204 p44/42 antibodies were used as control to determine the efficiency of the inhibitors. Total Src, Akt, p44/42 and RhoGDI were used as loading controls (F, H, and J). Quantification of at least three independent assays for PP2, LY294002, and U0126, respectively. For all experiments, RhoG activity is calculated as the ratio of active (RhoG-GTP)/total RhoG signal (RhoG-Tot) and expressed in arbitrary units (A.U.). All results are shown as mean ± SEM of at least three independent experiments.](1768fig3){#F3}

Src and PI3K control RhoG activation downstream from PDGFR
----------------------------------------------------------

RhoG activation by PDGF has not been described previously, and so we sought to characterize the signaling pathways involved in its activation. To this end, we tested whether inhibition of known PDGF-activated signaling pathways affected the rapid activation of RhoG. We measured the RhoG activation in response to PDGF levels in the presence or absence of the following inhibitors: Src (PP2 and SU6656), PI3K (LY294002), and p44/42 mitogen-activated protein kinase (MAPK; U0126). Our results show that inhibiting both Src and PI3K abolished the PDGF-mediated activation of RhoG, whereas inhibition of p44/42 MAPK had no effect ([Figure 3, E--J](#F3){ref-type="fig"}, and Supplemental Figure S2). These results suggest that RhoG activation downstream of PDGF depends on the activity of Src and PI3K but not on p44/42 MAPK.

Because both Src and PI3K appear to function upstream of RhoG after PDGF stimulation, we also analyzed their role in CDR formation. Both Src and PI3K play key roles during formation of CDRs in different cells lines ([@B74]; [@B59]; [@B68]). Our results confirm these reports and show that when either Src or PI3K is inhibited, formation of CDRs is dramatically reduced ([Figure 4, A and B](#F4){ref-type="fig"}). In the case of Src inhibition, formation of CDRs was completely abolished, whereas on PI3K inhibition, some CDRs were still observed. The few CDRs that formed were significantly smaller than those in CTRL cells ([Figure 4C](#F4){ref-type="fig"}).

![Effect of Src and PI3K inhibition on CDR formation. (A) A7r5 cells were serum starved for 2 h and then treated with 10 μM PP2 or 25 μM LY294002 for 30 min, followed by a 2.5-min treatment with PDGF-BB (20 ng/ml). Cells were then fixed and processed for immunofluorescence using cortactin (green) as marker of dorsal ruffles, Alexa 594--phalloidin (red) and Hoechst (blue). Scale bar, 20 μm. (B) Number of cells with CDRs expressed as percentage of cells that stained positive for at least one CDR. Results are shown as mean ± SEM from three independent experiments (≥200 cells per condition/experiment). (C) Average CDR area (shown only for CTRL and LY294002 treatment because PP2-treated cells did not form CDRs). Results are shown as mean ± SEM from three independent experiments (≥200 CDRs).](1768fig4){#F4}

Role of Rac1 and Cdc42 in CDR formation
---------------------------------------

Rac1 activity is required for CDR formation ([@B45]; [@B69]). There is also indirect evidence that Cdc42 plays a role in CDR formation ([@B47]; [@B14]; [@B41]). Because RhoG can act upstream of both Rac1 and Cdc42 ([@B26]; [@B38]; [@B23]), we investigated whether RhoG was acting through these GTPases during CDR formation. If RhoG's function during CDR formation depends on the downstream activation of Rac and/or Cdc42, then silencing or overexpressing Rac1 or Cdc42 should recapitulate the effects of RhoG KD or overexpression, respectively.

We compared the effects of silencing or overexpressing Rac1 or Cdc42 on CDR formation to those observed for RhoG KD or overexpression ([Figure 5](#F5){ref-type="fig"} and Supplemental Figure S3). As expected based on previous reports ([@B45]; [@B69]), our results show that Rac1 KD completely abolished CDR formation ([Figure 5, A and C](#F5){ref-type="fig"}). In contrast, the effects of Cdc42 KD were similar to those of RhoG, showing partial inhibition of CDR formation ([Figure 5, A and C](#F5){ref-type="fig"}). Similar to what we observed with RhoG KD, silencing Cdc42 significantly decreased the area of CDRs ([Figure 5D](#F5){ref-type="fig"}) without affecting the number of CDRs per cell ([Figure 5E](#F5){ref-type="fig"}). This decrease in area was comparable to that observed in RhoG KD cells ([Figure 5D](#F5){ref-type="fig"}). In Rac1 KD cells, only a small subset of cells formed ruffles (only 31 CDRs formed in \>2000 cells analyzed). Thus, even though the area of CDRs is smaller in Rac1 siRNA cells, the results may represent cells with incomplete KD. Of interest, simultaneous KD of RhoG and Cdc42 had an additive effect, with almost complete inhibition of CDR formation ([Figure 5C](#F5){ref-type="fig"}). However, the effect of the double KD on CDR area was not additive because the CDRs that were still able to form in the double KD (Cdc42/RhoG KD) cells were similar in size to those in the single KDs (RhoG KD or Cdc42 KD; [Figure 5D](#F5){ref-type="fig"}).

![Role of Rac1 and Cdc42 in CDR formation. (A) A7r5 cells were transfected with siRNA targeting RhoG (RhoG KD), Cdc42 (Cdc42 KD), Rac1 (Rac KD), or Cdc42 and RhoG combined (Cdc42/RhoG KD). Control cells were transfected with a nontargeting siRNA (siCTRL). (B) Cells were infected with a myc-tagged adenovirus control (CTRL) or with adenovirus encoding wild-type mycRhoG, mycCdc42, or mycRac or their constitutively active forms (mycRhoG Q61L, mycCdc42 Q61L, or mycRac Q61L). After 72 h, the cells were serum starved for 2 h and stimulated with PDGF-BB (20 ng/ml) for 2.5 min. In A, cells were then fixed and processed for immunofluorescence using cortactin (green) as marker of dorsal ruffles, Alexa 594--phalloidin (red), and Hoechst (blue), and in B, with cortactin (red), myc (green), and Hoechst (blue). Scale bar, 20 μM. (C--E) The experiments shown in A and B were quantified as follows: (C) percentage of cells with CDRs, (D) average CDR area, and (E) average number of CDR per cell (in cells positive for CDRs). Results are mean ± SEM from three independent experiments (≥100 cells per condition/experiment).](1768fig5){#F5}

With the exception of RhoG, the effect of overexpressing the Rho GTPases was not as pronounced as that of silencing them ([Figure 5, C--E](#F5){ref-type="fig"}). Supporting the results from the KD experiments, RhoG overexpression promoted a significant increase in the area of CDRs ([Figure 5D](#F5){ref-type="fig"}). Overexpression of a constitutively active form of RhoG (Q61L) showed an even greater increase in CDR area. RhoG overexpression also promoted a decrease in the percentage of cells showing CDRs ([Figure 5C](#F5){ref-type="fig"}), again more pronounced when the RhoG Q61L was expressed. These results suggest that too much or too little RhoG can affect CDR formation and that its activity needs to be tightly regulated. In contrast, overexpression of Cdc42, Rac1, or their constitutively active forms (Rac1 Q61L and Cdc42 Q61L) had no effect on the percentage of cells showing CDRs or the area of CDRs ([Figure 5, C and D](#F5){ref-type="fig"}). The combined expression of RhoG and Cdc42 showed an increase in CDR size similar in magnitude to that observed when RhoG alone was overexpressed, and in contrast to the double KD, no additive effect was observed. Finally, overexpression of RhoG, Rac1, or Cdc42 (wild type or Q61L) or RhoG/Cdc42 combined had no effect on number of CDRs per cell ([Figure 5E](#F5){ref-type="fig"}).

Taken together, these results suggest that RhoG functions independently of Rac and in parallel with Cdc42 to regulate pathways that function to control the formation of CDRs, as well as of their size.

Effects of RhoG KD on PDGF-induced Rac1 and Cdc42 activation
------------------------------------------------------------

It was previously shown that Rac can be activated downstream of RhoG through the RhoG effector ELMO, which forms a complex and activates the Rac-GEF Dock180 ([@B38]). In A7r5 cells, Rac1 is robustly activated after PDGF treatment as early as 1 min after treatment ([Figure 6A](#F6){ref-type="fig"}), as previously described in other cell lines ([@B51]). To test whether RhoG functions upstream or independently of Rac1, as suggested by the results from [Figure 5](#F5){ref-type="fig"}, we analyzed the effect of silencing RhoG on Rac1 activation in response to PDGF. In the absence of RhoG, Rac1 was efficiently activated by PDGF, suggesting that they are activated independently ([Figure 6, B and C](#F6){ref-type="fig"}). Even though the quantification shows that the absolute amount of active Rac1 is lower in RhoG KD cells (both with and without PDGF treatment), the relative increase of Rac1 activity between CTRL and PDGF-treated cells (the fold increase in nontreated vs. PDGF) was not significantly affected by the absence of RhoG ([Figure 6, B and C](#F6){ref-type="fig"}). These differences can be attributed to the decrease in Rac1 basal activity observed in nontreated cells after RhoG silencing ([Figure 6, B and C](#F6){ref-type="fig"}, lane 1 vs. lane 3). This was previously shown by others and is consistent with the fact that a fraction of Rac1 is activated by RhoG through ELMO/Dock180 ([@B38]; [@B51]; [@B58]). Our results suggest that in these cells, a small fraction of the basal activity of Rac1 depends on RhoG. However, Rac1 activation in response to PDGF is independent of RhoG. We observed a similar response when we analyzed Cdc42 activity. Cdc42 is activated robustly after PDGF treatment in control cells (Supplemental Figure S4A), confirming previous results in other cell lines ([@B36]), and it responds efficiently to PDGF when RhoG is knocked down, suggesting that it also functions independently of RhoG (Supplemental Figure S4B).

![RhoG silencing effect on Rac1 activation. (A) A7r5 cells were serum starved for 2 h and then stimulated with PDGF-BB (20 ng/ml) for 1, 2.5, and 5 min. Active Rac1 (Rac1-GTP) was then precipitated from total lysates using GST-PBD and immunoblotted with Rac1 antibodies. (B) A7r5 cells were transfected with siRNA targeting RhoG (RhoG KD) or with a nontargeting siRNA (CTRL). After 72 h, cells were serum starved for 2 h and then treated with PDGF-BB (20 ng/ml) for 1 min. Active Rac1 (Rac1-GTP) was precipitated from total lysates using GST-PBD and immunoblotted with the indicated antibodies. Tubulin was used as loading control. (C) Quantification of three independent assays. Rac-GTP is calculated as a ratio of active (Rac1-GTP)/total Rac1 (Rac1-Tot) signal and expressed in arbitrary units (A.U.).](1768fig6){#F6}

Trio regulates PDGF-mediated RhoG activation
--------------------------------------------

Trio is a RhoGEF that possesses two separate GEF domains, GEFD1 and GEFD2, which control the activity of Rac/RhoG and RhoA, respectively ([@B18]; [@B6]). It was previously shown that Trio regulates RhoG activity in the formation of actin-rich dorsal structures ([@B6]; [@B67]). Trio also colocalizes with the actin- and ICAM-rich rings that form during leukocyte transendothelial migration ([@B67]). To determine whether Trio is also involved in the regulation of RhoG during CDR formation, we first analyzed its localization in PDGF-treated A7r5 cells by immunofluorescence microscopy. Our results show that Trio colocalizes with F-actin at CDRs, suggesting that it may play a role in regulating RhoG during CDR formation ([Figure 7A](#F7){ref-type="fig"}). Silencing Trio expression using siRNA ([Figure 7, B and C](#F7){ref-type="fig"}) or inhibiting Trio using the chemical inhibitor ITX3 ([@B8]; [Figure 7, D and E](#F7){ref-type="fig"}) significantly decreased the activation of RhoG in response to PDGF. Both the basal levels of RhoG activation and its response to PDGF were reduced by ITX3. Even though Trio can act as both RhoG and Rac exchange factor, the reduction in Rac1 activity was not as pronounced as with RhoG, both at the basal level and in its response to PDGF ([Figure 7, F and G](#F7){ref-type="fig"}). Inhibition of Trio with ITX3 also caused a significant decrease in both the number of cells that form CDRs and the average CDR area without significantly affecting the number of CDRs per cell ([Figure 7, H--J](#F7){ref-type="fig"}). These results are almost identical to those observed in RhoG KD cells ([Figure 1](#F1){ref-type="fig"}) and suggest that activation of RhoG in response to PDGF is mediated by Trio during PDGF-mediated CDR formation, whereas activation of Rac1 may be mediated by a different GEF.

![Trio regulates RhoG activation and CDR formation. (A) A7r5 cells were serum starved for 2 h and stimulated with PDGF-BB (20 ng/ml) for 2.5 min. Cells were then fixed and processed for immunofluorescence using Trio antibody (red), Alexa 488--phalloidin (green), and Hoechst (blue) to stain the nucleus. Scale bar, 20 μm. (B) A7r5 cells transfected with a siRNA targeting Trio (Trio KD) or nontargeting siRNA (CTRL) were serum starved for 2 h and then stimulated with PDGF-BB (20 ng/ml) for 1 min. Active RhoG (RhoG-GTP) was precipitated from total lysates using GST-ELMO and immunoblotted for RhoG. (C) Quantification of at least three independent assays. RhoG-GTP is calculated as the ratio of active/total RhoG signal and expressed in arbitrary units (A.U.). (D**)** Serum-starved A7r5 cells were preincubated with the Trio inhibitor ITX3 (100 μM) or with DMSO (CTRL) and then stimulated with PDGF-BB (20 ng/ml) for 1 min. Active RhoG (RhoG-GTP) was precipitated from total lysates using GST-ELMO and immunoblotted with the indicated antibodies. (E) Quantification of at least three independent assays. RhoG-GTP is calculated as the ratio of active/total RhoG signal and expressed in arbitrary units (A.U.). (F) Serum-starved A7r5 cells were preincubated with the Trio inhibitor ITX3 (100 μM) or with DMSO (CTRL) and then stimulated with PDGF-BB (20 ng/ml) for 1 min. Active Rac1 (Rac-GTP) was precipitated from total lysates using GST-PBD and immunoblotted with the indicated antibodies. (G) Quantification of at least three independent assays. Active Rac1 (Rac1-GTP) is calculated as the ratio of active/total Rac1 signal and expressed in arbitrary units (A.U.). (H) A7r5 cells were preincubated with ITX3 (100 μM) or DMSO (CTRL) and stimulated with PDGF-BB (20 ng/ml) for 2.5 min. Cells were fixed and processed for immunofluorescence using cortactin (green) as marker of dorsal ruffles, Alexa 594--phalloidin (red), and Hoechst (blue). Scale bar, 20 μm. Quantification of (I) percentage of cells with CDRs, (J) average area of each CDR, and (K) number of CDRs per cell (in cells positive for CDRs). Black bars, CTRL; gray bars, ITX3. Results are mean ± SEM from three independent experiments (≥100 cells per condition/experiment).](1768fig7){#F7}

Effects of RhoG and Trio silencing during macropinocytosis and receptor internalization
---------------------------------------------------------------------------------------

What is the functional consequence of having smaller CDRs? One possibility is that smaller CDRs could be associated with dysfunctional endocytic process. [@B31] showed that silencing ARAP1, which reduces CDR area, inhibits dextran uptake through macropinocytosis. To determine whether RhoG plays a role during macropinocytosis, we analyzed the uptake of fluorescent-labeled dextran in A7r5 cells transfected with siRNA targeting RhoG. Our results show that PDGF treatment for 30 min stimulated dextran uptake ([Figure 8, A and B](#F8){ref-type="fig"}). However, when RhoG expression was silenced, PDGF-mediated stimulation of dextran uptake was reduced to levels comparable to that in nontreated cells. Reexpression of mycRhoG (siRNA resistant) in RhoG KD cells restored levels of dextran uptake to control levels ([Figure 8, A and B](#F8){ref-type="fig"}). A similar reduction in dextran uptake was observed when Trio expression was silenced ([Figure 8, C and D](#F8){ref-type="fig"}). We were able to rescue the dextran uptake by reexpressing Trio-D1 green fluorescent protein (GFP; encoding the catalytic domain that activates Rac/RhoG; [@B66]).

![RhoG regulates macropinocytosis. A7r5 cells were transfected with the indicated siRNAs. RhoG or Trio expression was then rescued with adenovirus infection of mycRhoG or TrioD1-GFP, respectively. After 2 h of serum starvation, cells were incubated with 250 μg/ml Alexa Fluor 594--conjugated dextran (10,000 molecular weight) with or without 20 ng/ml PDGF-BB for 60 min. Cells were then lysed, and dextran internalization was measured at 590/617 nm in a fluorometer. Dextran concentration in each sample was extrapolated by a dextran standard curve, normalized by the amount of protein in each condition, and expressed as nanograms of dextran/microgram of protein. Results are shown as mean ± SEM from three independent experiments. (A) Effects of RhoG KD and rescue on dextran internalization. (B) The efficiency of RhoG KD and rescue was analyzed by immunoblotting with the indicated antibodies. (C) Effects of Trio KD and rescue on dextran internalization. (D) The efficiency of Trio KD and rescue (Trio-D1-GFP) was analyzed by immunoblotting with the indicated antibodies. (E) Internalization of PDGFR was assessed by protection to trypsin digestion assay as described in *Materials and Methods*. Cells transfected with siRNA targeting RhoG (RhoG KD) or a nontargeting control (CTRL) were serum starved for 2 h and stimulated with 20 ng/ml PDGF-BB for the indicated times. After trypsin digestion, cell lysates were analyzed by immunoblot for the indicated antibodies. PDGFR observed in this assay corresponds to the internalized fraction of receptor (protected from trypsin). RhoG blot shows the efficiency of knockdown. RhoGDI was used as a loading control. (F) To rule out changes in total levels of PDGFR between CTRL and RhoG KD, cells were treated as in E, incubated for 30 min with PDGF, and processed for immunoblotting without trypsin treatment.](1768fig8){#F8}

It was previously shown that PDGFR, as well as other tyrosine kinase receptors and integrins, can be internalized by macropinocytosis to modulate proliferation and cell migration ([@B76]; [@B44]; [@B53]; [@B40]; [@B29]; [@B60]; [@B79]). To determine whether PDGFR internalization is affected after RhoG silencing, we performed a trypsin-protection digestion assay ([@B13]). In this assay, cells are treated with trypsin to digest the fraction of the proteins present at the plasma membrane. The cells are then lysed and immunoblotted to detect the fraction that was "protected" from the trypsin digestion (internalized fraction). Our results show that in control cells, the pool of PDGFR protected from trypsin digestion increased soon after PDGF stimulation (30 min), suggesting that it gets rapidly internalized in response to PDGF. A significant fraction remains in the "protected" fraction even after 6 h of stimulation ([Figure 8E](#F8){ref-type="fig"}, CTRL). In contrast, in RhoG KD cells, the fraction of PDGFR internalized was drastically decreased, suggesting that, in the absence of RhoG, most of the PDGFR remains on the cell surface after PDGF stimulation ([Figure 8E](#F8){ref-type="fig"}, RhoG KD). This was not due to differences in the total PDGFR levels between CTRL and RhoG KD, because we did not observe any changes before or after PDGF treatment ([Figure 8F](#F8){ref-type="fig"}).

Role of RhoG and Trio in vascular smooth muscle cell migration
--------------------------------------------------------------

Previous work showed that CDRs might be involved in cell migration, when cells switch from a static to a migratory phenotype ([@B44]; [@B61]). To test the role of RhoG and Trio during PDGF-mediated migration, we used the xCELLigence real-time cell analyzer (RTCA), which uses noninvasive electrical impedance to monitor cell migration in real time. As previously demonstrated for many cell types ([@B3]), PDGF treatment also stimulates migration in A7r5 cells ([Figure 9, A and B](#F9){ref-type="fig"}, red vs. green line). However, when RhoG expression is silenced ([Figure 9, A and E](#F9){ref-type="fig"}, magenta line) or Trio is inhibited ([Figure 9B](#F9){ref-type="fig"}, magenta line), migration in the presence of PDGF is significantly impaired. In the absence of PDGF, however, we do not observe significant inhibition in migration when RhoG is silenced or Trio is inhibited ([Figure 9, A and B](#F9){ref-type="fig"}, red and blue lines). In supporting of these results, RhoG silencing inhibited wound healing in response to PDGF, suggesting that migration is impaired in the absence of RhoG activity ([Figure 9, C--E](#F9){ref-type="fig"}).

![RhoG and Trio regulate chemotaxis toward PDGF. (A) Real-time migration was performed with an xCELLigence RTCA DP System using CIM-plate 16. RhoG KD (shRhoG) or control (CTRL) cells were seeded on the upper part of the chamber and allowed to migrate toward a lower chamber containing 20 ng/ml PDFG-BB. (B) Alternatively, cells were allowed to migrate as described in the presence of 100 μM ITX3 or the equivalent volume of DMSO. Impedance measure every 5 min during the first 6 h of migration expressed as delta cell index, with each point corresponding to the average of three or four wells (±SD). Each graph is representative of three independent experiments. (C) Analysis of wound closure in a confluent monolayer of control or RhoG siRNA--transfected A7r5 cells (RhoG KD). Cells were imaged at different time points to monitor wound closure. Representative images for control (CTRL) and RhoG KD cells (RhoG KD) at 0 and 16 h after wounding. (D) Wound area at 0 and 16 h (error bars represent SEM; *n* = 3). (E) KD efficiency for A (left, shRNA-mediated KD) and C and D (right, siRNA-mediated KD) was analyzed by SDS--PAGE and Western blotting. (F) Working model. RhoG functions both upstream of Rac1 and contributes to regulate the formation of CDRs and independently of Rac1, where it functions downstream of Trio to regulate the size of the CDRs formed. Cdc42 also controls CDR formation and size, probably downstream of the Cdc42 GEF Tuba.](1768fig9){#F9}

In summary, our results suggest that PDGF promotes the activation of RhoG. Activation of RhoG downstream of PDGF is regulated by the exchange factor Trio and plays a role in the formation of PDGF-mediated CDRs and the functions associated with CDR formation, including macropinocytosis, receptor internalization, and cell migration.

DISCUSSION
==========

In this study, we demonstrate a role for the small GTPase RhoG and its exchange factor, Trio, in the regulation of CDRs downstream of PDGF. Our results show that Trio and RhoG influence the number of cells that form CDRs, as well as their size. Our working model proposes that a pool of RhoG functions upstream of Rac1, which in turn modulates formation of CDRs, whereas a second pool of RhoG functions downstream of Trio but independently of Rac1 to regulate the size of the CDRs formed ([Figure 9F](#F9){ref-type="fig"}). We also found that Trio and RhoG modulate cellular processes associated with CDR formation, including micropinocytosis, receptor internalization, and cell migration.

Our results show that in rat vascular smooth muscle cells (A7r5) and human fibroblasts (MRC5), PDGF treatment stimulates a rapid and transient activation of RhoG, a process that requires the PDGFR kinase activity. In HeLa cells, RhoG can be activated in response to epidermal growth factor (EGF) but not PDGF or serum, suggesting that this response may be cell-type specific ([@B58]). The activation of RhoG downstream of PDGF requires both Src and PI3K. Again, this is in contrast to results in HeLa cells, in which inhibiting Src or PI3K had no effect on EGF-mediated RhoG activation ([@B58]). Taken together, these results suggest a different mechanism for RhoG activation downstream of PDGFR than with EGFR.

Silencing RhoG expression affects CDRs in two different ways. First, it reduces the number of cells that form CDRs in response to PDGF, and second, it induces a dramatic decrease in the average size of the CDRs that form. We believe that the decrease in CDR number may be related to the influence of RhoG on Rac1 activity. RhoG functions are frequently mediated by the downstream activation of Rac1 because the RhoG effector ELMO forms a complex with Dock180, which functions as a GEF for Rac ([@B30]; [@B9]; [@B38]). Rac1 plays a key role during CDR formation. Rac-null fibroblasts do not have CDRs ([@B69]), whereas dominant-negative Rac abolishes both CDRs and peripheral ruffles ([@B62]; [@B45]). Our results agree with these findings and show that silencing Rac1 virtually eliminates CDR formation in response to PDGF. In A7r5 cells, Rac1 is efficiently activated in response to PDGF, even after RhoG silencing, suggesting that its ability to respond to PDGF is independent of RhoG. Similar results were reported in MEFs treated with PDGF ([@B51]) and in HeLa cells in response to EGF ([@B58]). There was a slight reduction, however, in the basal level of Rac1 in RhoG KD cells and the total levels of active Rac1 after PDGF treatment, suggesting that a fraction of Rac1 is activated downstream of RhoG, probably via ELMO-Dock180. This reduction in Rac1 activity may be responsible for the decrease in number of cells that form CDRs when RhoG is silenced.

Inhibition of either Src or PI3K also inhibited CDR formation, as previously shown ([@B72]; [@B74]; [@B59]; [@B68]). The fact that inhibiting Src or PI3K has a significantly stronger effect on CDR than silencing RhoG is not surprising because they both regulate a wide variety of signaling pathways downstream PDGFR. It also makes it difficult to analyze the specific roles of Src and PI3K on RhoG activation downstream of PDGF. In the case of PI3K inhibition, it most likely affects CDR formation through Rac1, which was shown to be activated downstream of PI3K in PDGF-treated cells ([@B32]).

The mechanisms that control ring size in CDRs are not completely understood. [@B31] showed that ARAP1, a GAP for Arf and Rho GTPases, can regulate ring size. In ARAP1 KD cells, CDR rings are smaller, whereas overexpression of ARAP1, as well as of dominant-negative forms of Arf1 and Arf5, resulted in larger rings ([@B31]). Catalytic dead mutants in the Arf-GAP domain but not in the Rho-GAP domain abolished the overexpression effect, suggesting that it is mediated via the function of Arf1/Arf5 and not Rho proteins ([@B31]). It is possible that RhoG function on CDR area may occur in conjunction Arf1/5 inactivation by ARAP1. Cross-talk was found between Arf and Rho GTPases ([@B7]; [@B73]). However, further experiments are necessary to determine whether these two pathways are connected.

We can only speculate about the mechanism by which RhoG controls CDR size. One possible explanation is that RhoG regulates the initial expansion of the CDRs. As mentioned earlier, CDRs form at or close to the maximum size and then start closing rapidly. This quick expansion occurs rarely and is extremely fast, and so we were not able to measure the expansion rate of the CDRs accurately in CTRL and RhoG KD cells. Another possibility is that RhoG regulates the turnover in the CDR machinery required for the CDRs to open/close. Modeling work showed that CDRs behavior can be described as propagation of a wave in an excitable medium ([@B78]). This process involves spatiotemporal regulation of actin polymerization/depolymerization, myosin-mediated contractility, and regulation of membrane curvature ([@B2]). Each of these processes can be controlled by Rho GTPases. We recently described a role for RhoG in the turnover of invadopodia in breast cancer cells ([@B28]). Invadopodia have many components in common with CDRs ([@B27]), and it is possible that RhoG plays a similar role in CDRs, regulating the turnover required during the expansion or closing of CDRs. In contrast to RhoG, Rac1 overexpression had no significant effect in the area of CDR, suggesting a more fundamental role in CDR formation. These results agree with reports that RhoG may function independently of Rac1 via specific effectors ([@B71]), and that Rac1 activation alone is not sufficient for CDR formation ([@B62]; [@B45]). The identity of the RhoG effectors involved in the regulation of CDRs is not known and is the focus of our future studies.

Cdc42 was associated with CDR function in studies that characterized the role of its downstream effectors, including N-WASP/Arp2/3, CIP4, and PAK1/2 ([@B36]; [@B46]; [@B63]). In addition, the BAR domain--containing Cdc42 GEF Tuba was shown to recruit N-WASP and dynamin to CDRs and stimulate their formation ([@B42]; [@B55]). Of interest, we show in this study that silencing Cdc42 expression reduces both the number of cells forming CDRs and the area of CDRs in a manner similar to that of silencing RhoG, suggesting that there may be cross-talk between RhoG and Cdc42. Supporting these results, when the Cdc42 effector N-WASP is knocked out in cells, the area of CDRs is approximately threefold smaller than in control cells ([@B46]). RhoG was previously shown to influence Cdc42 function, both positively and negatively, via yet-uncharacterized mechanisms ([@B26]; [@B23]). Our results suggest that RhoG and Cdc42 regulate the CDR ring size independently and that CDR formation and ring size may be controlled by different pathways. First, Cdc42 was robustly activated after PDGF treatment, as shown in other cell types ([@B36]; [@B77]; [@B63]), but its activation was not affected by RhoG KD. Second, the effects of silencing RhoG and Cdc42 were additive in relation to the number of cells forming CDRs but not on CDR area. Finally, overexpression of Cdc42 did not increase CDR area as observed with the overexpression of RhoG.

A number of GEFs have been described that stimulate nucleotide exchange of RhoG, including SGEF, PLEKHG6, Ephexin 4, Trio, and P-REX1 ([@B5]; [@B6]; [@B48]; [@B71]; [@B21]; [@B12]; [@B16]; [@B43]; [@B15]). Here we focused on Trio because it was previously associated with the regulation of diverse actin structures at the dorsal surface of the cells. Trio and RhoG are involved in the formation of peripheral dorsal ruffles ([@B5]; [@B6]), as well as in the regulation of phagocytosis ([@B17]) and transendothelial migration ([@B67]). Trio and kalirin are the only members of the mammalian Dbl family that display two GEF domains of distinct specificity ([@B18]). The first GEF domain of Trio (Trio GEFD1) activates RhoG and Rac, and the second (Trio GEFD2) acts on RhoA, which suggest that Trio may link several GTPase pathways in vivo ([@B5]; [@B6]).

Our immunofluorescence work shows that endogenous Trio localizes to CDRs. This result by itself should be taken with caution because staining three-dimensional structures such as CDRs often produces false positives. However, our results also show that Trio is the GEF responsible for the regulation of RhoG downstream of PDGF and that, just as we observe for RhoG, it affects the number of cells that make CDRs, as well as the size of the CDRs. Of interest, inhibiting Trio selectively reduced RhoG activation and not Rac1 downstream of PDGFR, suggesting that Rac1 activation downstream of PDGF may be mediated by a different GEF. These results agree with findings showing that Trio has a higher affinity for RhoG than Rac1 ([@B6]) and that TrioD1 inhibition with ITX3 did not completely abolish Rac1 activation ([@B66]). Our results do not exclude the involvement of other RhoGEFs that may act in conjunction with Trio to regulate this pathway. Other signals upstream of RhoG and/or Rac1 and Cdc42 may include the adaptor protein Nck, which was shown to play a role in the regulation of Rho GTPases and actin dynamics downstream of the PDGF receptor and is also required for the formation of CDRs ([@B56]). We plan to investigate the role of Nck in the regulation of RhoG and other GTPases during CDR formation.

One of the most important cellular functions associated with CDR formation is macropinocytosis. The formation of CDRs has been associated with internalization of both fluid-phase components ([@B20]) and growth factor receptors and other transmembrane proteins ([@B53]; [@B29]). RhoG has also been associated with macropinocytosis ([@B21]), internalization of integrins ([@B4]), and phagocytosis ([@B64]). Trio has been associated with phagocytosis of apoptotic cells by activating RhoG and ELMO-DOCK180-Rac complex ([@B17]) but not directly with macropinocytosis. Our results show that silencing RhoG or Trio inhibits both macropinocytosis, as measured by dextran uptake, and internalization of the PDGF receptor, suggesting that it may be playing a role in receptor recycling. This decrease in dextran uptake and receptor internalization may result from the observed decrease in CDR size when RhoG or Trio is silenced, as CDR ring size is correlated with a decrease in macropinocytosis in ARAP1-knockdown cells ([@B31]). In migrating cells, macropinocytosis contributes to the recycling of growth factor receptors and integrins from disassembling focal adhesion to the leading edge ([@B29]). Both RhoG and Trio were previously associated with roles in migration ([@B37]; [@B33]; [@B4]; [@B66]) and also play a role in regulating PDGF-mediated migration in our system.

In summary, our results describe a novel role for Trio and RhoG in the regulation of CDR size, which affects macropinocytosis, receptor recycling and internalization, and cell migration.

MATERIALS AND METHODS
=====================

Antibodies and other reagents
-----------------------------

The following antibodies were used: mouse monoclonals anti-RhoG and anti-myc (9E10), rabbit anti-cortactin and anti-RhoGDI1, goat anti-Trio, and rabbit anti-fibronectin (Santa Cruz Biotechnology); mouse anti--α-tubulin and anti-vinculin (Sigma-Aldrich); total-Akt, rabbit anti--phospho-Akt (S473), rabbit anti-Src, rabbit anti--phospho Src (Y416), rabbit anti p44/42 MAPK, rabbit anti--phospho-p44/42 (Thr-202/Tyr-204), and rabbit monoclonal anti--PDGFR β (Cell Signaling); mouse monoclonals anti-Rac1 and anti-Cdc42 (BD Biosciences); mouse anti-GFP (Thermo Fisher); mouse anti-actin (Abcam); Alexa Fluor 488 and Alexa Fluor 594 anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG-conjugated secondary antibodies and Alexa 488 and Alexa 594--phalloidin (Life Technologies); and horseradish peroxidase (HRP)--conjugated anti-mouse, anti-rabbit, and anti-goat secondary antibodies (Jackson ImmunoResearch).

Cell culture
------------

Rat embryonic thoracic aorta smooth muscle--derived cells (A7r5) were obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 1 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies) at 37°C in a humidified atmosphere of 95% air and 5% CO~2~. After the attainment of 70--80% confluence, the cells were incubated in serum-free DMEM during 2 h. In some experiments, cells were preincubated with the Src inhibitors SU6656 (Calbiochem) at 2.5 μM or PP2 (Sigma-Aldrich) at 10 μM, PI3K inhibitor (LY-294002; Calbiochem) at 25 μM, MEK1/2 inhibitor U0126 (Sigma-Aldrich) at 10 μM, Trio inhibitor (ITX-3; Tocris) at 100 μM, or the equivalent amount of dimethyl sulfoxide (DMSO) during 30 min and then stimulated with 20 ng/ml PDGF-BB (Invitrogen) during 1 min for GTPase activity assays or 2.5 min for immunofluorescence assay.

Rho GTPase activity assays
--------------------------

To determine the levels of active RhoG, Rac1, and Cdc42, A7r5 cells were growth until 70--80% confluence and serum starved for 2 h. The cells were then washed twice with ice-cold Tris-buffered saline (50 mM Tris, pH 7.4, 5 mM MgCl~2~, 150 mM NaCl) and then lysed in lysis buffer (50 mM Tris, pH 7.4, 10 mM MgCl~2~, 150 mM NaCl, 1% Triton X-100, EZBlock Protease Inhibitor Cocktail \[BioVision\]). Lysates were cleared by centrifugation at 16,000 × *g* for 3 min, and protein concentrations of the supernatants were determined using the DC Protein Assay (Bio-Rad). Equal amounts of total protein were incubated during 30 min with rotation at 4°C with 50 μg of glutathione-Sepharose beads (GE Healthcare) loaded with glutathione *S*-transferase (GST)--ELMO (full-length ELMO for RhoG) or GST-PBD (Pak1-binding domain for Rac and Cdc42). The beads were washed three times with lysis buffer, and pull downs and lysates were immunoblotted using antibodies for RhoG, Rac1, or Cdc42, respectively.

Cell transfection and adenoviruses
----------------------------------

A7r5 cells were transfected using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol. The siRNA was used to a final concentration of 25 nM, with the sequences specific for rat RhoG, 5-CGUCUUCGUCAUCUGUUUCUU-3; Cdc42 and Rac (ON-TARGETplus SMARTpool); and Trio, 5-GAA­CAUGAUUGACGAGCAU\[dT\]\[dT\]-3. After 72 h of transfection, cells were serum starved for 2 h and then stimulated with 20 ng/ml PDGF-BB during 1 min for pull-down assays or 2.5 min for immunofluorescence assays.

The ViraPower Adenoviral Expression System (Life Technologies) was used for transient expression of human mycRhoG, mycRhoG Q61L, mycRac, mycRac Q61L, mycCdc42, and mycCdc42 Q61L, which were subcloned into pAd/CMV/V5-DEST using Gateway recombination according to the manufacturer's instructions (Life Technologies). pAdeno-TrioD1-GFP was a gift of Jaap vanBuul (Sanquin, Netherlands). Adenovirus was prepared according to manufacturer's recommendations (Life Technologies).

For the overexpression experiments or rescue, cells were infected for 48 h with the indicated viruses. The efficiency of the overexpression was further determined for each assay by immunoblotting using specific antibodies as indicated in the respective figures.

Cell lysis and immunoblotting
-----------------------------

Cells cultured on 100-mm tissue culture dishes were briefly rinsed with phosphate-buffered saline (PBS) and then scraped into a lysis buffer containing 50 mM Tris/HCl, pH 7.4, 10 mM MgCl~2~, 150 mM NaCl, 1% Triton X-100, and EZBlock Protease Inhibitor Cocktail. The supernatant was collected after centrifugation at 14,000 rpm for 10 min. For immunoblotting, lysates were boiled in 2× Laemmli buffer, and 20 μg of protein was resolved by SDS--PAGE in each lane of a 13% gel. The proteins were transferred to polyvinylidene fluoride, immunoblotted with the indicated antibodies, and visualized using the Immobilon Western Millipore Chemiluminescence HRP substrate (Millipore). Blots were developed using either film or an Azure c600 chemiluminescence detector (Azure Biosystems).

Immunofluorescence
------------------

A7r5 cells were seeded in six-well plates, and after 16 h, they were either transfected with siRNA against RhoG, Rac1, or Cdc42 or infected with adenoviruses encoding myc-Rac, myc-Cdc42, or myc-RhoG (or their constitutive active forms) for 48 h (empty virus as control). After that, cells were trypsinized, seeded on coverslips precoated with 10 μg/ml fibronectin, and allowed to attach for 16 h. Cells were then serum starved for 2 h and stimulated with 20 ng/ml PDGF-BB for indicated times. Immunofluorescence assay was performed as described previously ([@B25]). Briefly, cells were fixed for 10 min with 3.7% paraformaldehyde and quenched with 10 mM ammonium chloride. Cells were then permeabilized with 0.1% Triton X-100 in PBS. The coverslips were then washed with PBS and blocked in PBS, 2.5% goat serum, and 0.2% Tween 20 for 5 min, followed by 5 min of blocking in PBS, 0.4% fish skin gelatin, and 0.2% Tween 20. Cells were incubated with primary antibody for 1 h at room temperature. Coverslips were washed with PBS and 0.2% Tween 20 and incubated with secondary antibodies for 45 min, washed as described, and mounted on glass slides in Mowiol mounting solution. Images were acquired on an Olympus IX81 inverted microscope using a PlanApo N 60×/1.42 oil objective lens and a XM10 camera (Olympus). All experiment were repeated three independent times, and from each one, at least 100 cells/condition were analyzed by counting the percentage of cells with CDR, the number of CDRs per cell, and the area of each CDR. The area was calculated by drawing the outline of each ruffle and measuring it using ImageJ software (National Institutes of Health, Bethesda, MD).

Live imaging
------------

Dynamics of CDR formation was imaged by differential interference contrast (DIC) on an Olympus VivaView FL microscope using a UPLSAPO 20×, numerical aperture 0.75, DIC objective and a Hamamatsu ORCA II camera. Cells were stabilized for 30 min in the incubator before the addition of PDGF. Images were acquired every 35 s. Six different samples (three CTRL and three RhoG KD) were analyzed in parallel for every experiment, and five fields were imaged simultaneously for each of the samples. CDR properties were measured in every frame for each ruffle using ImageJ as described.

PDGF receptor internalization by trypsinization
-----------------------------------------------

PDGFR internalization was determined by evaluating the amount of receptor resistant to trypsin digestion ([@B13]). In brief, cells were transfected with siRNA against RhoG or control as described, serum starved for 2 h, and stimulated with 20 ng/ml PDGF-BB for 0.5, 2, and 6 h. Cells were washed twice with PBS and incubated for 8 min on ice with ice-cold 20 mM sodium acetate, pH 3.7. Afterward, cells were washed with ice-cold PBS and incubated with 0.05% trypsin on ice for 30 min. The reaction was stopped by adding soybean trypsin inhibitor (1 mg/ml), and then cells were washed with PBS and scraped in lysis buffer (50 mM Tris, pH 7.4, 10 mM MgCl~2~, 150 mM NaCl, 1% Triton X-100, EZBlock Protease Inhibitor Cocktail). Samples were analyzed by SDS--PAGE 10%, followed by immunoblots for PDGFR (Cell Signaling) and RhoG (Millipore) to evaluate the efficiency of knockdown, with GDI as a loading control.

Wound-healing assay
-------------------

A7r5 cells were seeded to confluence and transfected with siRNA control or siRNA against RhoG as described. After 48 h, cells were serum starved for 2 h before the monolayer was scratched using a micropipette tip. Cells were then incubated with medium containing 20 ng/ml PDGF-BB for 16 h. Pictures were captured at 0 and 16 h, and the wound area was measured using ImageJ. Results are expressed as percentage of wound area relative to the initial area at time zero.

Dextran assay
-------------

To determine the levels of dextran uptake, A7r5 cells were transfected with siRNA against RhoG, Trio, or control. After 24 h of transfection, the expression of RhoG was rescued by infecting the cells with an adenovirus coding myc-RhoG. Cells were then serum starved for 2 h using DMEM without phenol red and 0.15% lipid-free bovine serum albumin (BSA; 48 h after transfection/24 h after infection). Cells were then incubated with Ringer's buffer (155 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 2 mM NaH~2~PO~4~, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 10 mM [d]{.smallcaps}-glucose, pH 7.2, plus 0.05% lipid-free BSA) containing 250 μg/ml dextran, 10,000 molecular weight, conjugated to Alexa Fluor 594 (Invitrogen) with or without 20 ng/ml PDGF-BB for 30 min. Plates were rinsed three times with iced-cold Ringer's buffer and washed by immersion in 1 l of iced-cold PBS three times for 5 min each time. After that, cells were lysed with 500 μl of 0.5% Triton X-100 in PBS and incubated at 37°C. Fluorescence was determined in duplicate at 590 nm (excitation) and 617 nm (emission) with a Spectramax M5 microplate reader (Molecular Devices). Dextran concentration in each sample was determined by a dextran standard curve, normalized by the amount of protein in each condition, and expressed as nanograms of dextran/microgram of protein.

Real-time cell analysis experiments
-----------------------------------

Experiments of real-time migration were performed with the xCELLigence RTCA DP Instrument (Roche) using the CIM-plate 16. Briefly, cells lines either infected with lentivirus encoding short hairpin RNA targeting RhoG or with a noncoding virus as control (CTRL; Open Biosystems) were serum starved for 2 h. A total of 25,000 cells were seeded on the upper part of the chamber in DMEM 0.5% lipid free-BSA and allowed to migrate toward a lower chamber containing DMEM 0.1% FBS or DMEM 0.1% FBS and 20 ng/ml PDGF-BB. In other assays, A7r5 cells were allowed to migrate as described in the presence of 100 μM ITX3 or the equivalent volume of DMSO. Changes in the impedance were assessed every 5 min for 16 h. A representative graph from three independent experiments shows the first 6 h of migration expressed as delta cell index, with each point corresponding to the average of three of four wells (±SD).

Statistical analysis
--------------------

Statistical analysis was performed using GraphPad Prism 7. One-way analysis of variance was used to compare multiple-condition assays and unpaired *t* test to compare the means of two independent groups.
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CDR

:   circular dorsal ruffle

GAP

:   GTPase-activating protein

GEF

:   guanine nucleotide exchange factor

PDGF

:   platelet-derived growth factor

PR

:   peripheral ruffle
